Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
467 0
SM ISO690:2012
RAVENSCROFT, Luke, KETTLE, Stewart, PERSIAN, Ruth, RUDA, Simon, SEVERIN, Lilian, DOLTU, Svetlana, SCHENCK, Benjamin, LOEWENSTEIN, George. Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova. In: European Respiratory Journal, 2020, vol. 56, p. 0. ISSN 0903-1936. DOI: https://doi.org/10.1183/13993003.00493-2020
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
European Respiratory Journal
Volumul 56 / 2020 / ISSN 0903-1936 /ISSNe 1399-3003

Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova

DOI:https://doi.org/10.1183/13993003.00493-2020

Pag. 0-0

Ravenscroft Luke1, Kettle Stewart1, Persian Ruth1, Ruda Simon1, Severin Lilian2, Doltu Svetlana2, Schenck Benjamin3, Loewenstein George3
 
1 Behavioural Insights Team, London,
2 Act For Involvement, Chișinău,
3 Carnegie Mellon University, Pittsburgh, USA
 
 
Disponibil în IBN: 27 august 2020


Rezumat

INTRODUCTION: The effectiveness of video-observed therapy (VOT) for treating tuberculosis (TB) has not been measured in low- and middle-income countries (LMICs), where >95% of TB cases and deaths occur. In this study, we analyse the effectiveness and patient cost-difference of VOT compared to clinic-based directly observed therapy (DOT) in improving medication adherence in Moldova, a LMIC in Eastern Europe. METHODS: The study was a two-arm individually randomised trial with 197 TB patients (n=99 DOT control group; n=98 VOT treatment group; multidrug-resistant TB cases were excluded). The primary outcome was observed medication adherence, measured by the number of days that a patient failed to be observed adhering to medication for every 2-week period during the course of their treatment. RESULTS: VOT significantly decreased nonadherence by 4 days (95% CI 3.35-4.67 days, p<0.01) per 2-week period: 5.24 days missed per 2-week period for DOT and 1.29 days for VOT. VOT patients spent MDL 504 (∼EUR 25) (95% CI MDL 277-730, p<0.01) and 58 h (95% CI 48-68 h, p<0.01) less on their treatment. In addition, VOT increased self-reported satisfaction with treatment. We found no significant results pertaining to treatment success, patient wellbeing or patient employment status and some evidence of an increase in side-effects. DISCUSSION: In this trial, VOT increased observed medication adherence for TB patients in Moldova, a LMIC, when compared to clinic-based DOT. Additionally, VOT significantly reduced the time and money patients spent on their treatment.

Cuvinte-cheie
pulmonary tuberculosis, Multidrug Resistant Tuberculosis, Directly Observed Therapy